Randomized Clinical Trial of Prehospital Sodium Nitrite in Out-of Hospital Cardiac Arrest Patients

Francis Kim MD, Charles Maynard PhD, Cameron Dezfulian MD, Michael Sayre MD, Peter Kudenchuk MD, Thomas Rea MD, Deborah Sampson RN, Michele Olsufka RN, Susanne May PhD, Graham Nichol MD MPH

University of Washington Seattle, WA

Background

- Survival from OHCA is less than 20%
- Administration of sodium nitrite during resuscitation increased survival by nearly 50% in animal model of cardiac arrest
- Determine whether sodium nitrite given during resuscitation improves outcomes from out-of-hospital cardiac arrest

Trial Setting/Design


- Emergency medical services (EMS) agencies in Seattle and surrounding King County
- Individual OHCA patients double blind-randomized (1:1:1)
 - Intervention- 60 mg Sodium Nitrite
 - Intervention- 45 mg Sodium Nitrite
 - Control-Placebo (normal saline)

Eligibility

Inclusion Criteria
Cardiac arrest with life
support by paramedics
Age 18+
Intravenous/intraosseous
access
Unconscious

Exclusion Criteria
Traumatic cardiac arrest
Age < 18
Known DNR
Pregnant
Prisoner
Drowning


Trial Flow



Primary Outcome: Survival to Hospital Admission, Important Secondary: Survival to Discharge


Characteristic		Randomization group		
	60 mg (n=497)	45 mg (n=499)	Placebo (n=496)	
Age (years)	62 <u>+</u> 17	65 <u>+</u> 16	64 <u>+</u> 17	
Men	66%	66%	67%	
Initial rhythm				
Asystole	44.1%	45.9%	41.3%	
Pulseless electrical activity	27.4%	30.9%	29.6%	
Ventricular fibrillation	24.9%	19.0%	23.6%	
Ventricular tachycardia	0.4%	0.2%	0.4%	
Arrest before EMS arrival	87%	87%	90%	
Witnessed arrest	43%	43%	44%	
Time from call to first arrival (min)	5.7 <u>+</u> 2.0	6.1 <u>+</u> 3.3	6.0 <u>+</u> 4.5	
Time from call to randomization (min)	22 <u>+</u> 8 (n=493)	22 <u>+</u> 10 (n=498)	22 <u>+</u> 10 (n=491)	

Outcomes - Survival to Hospital Admission



All Cardiac arrest 60 mg n= 212 45 mg n= 205 Placebo n= 218 VF 60 mg n=84 45 mg n=70 Placebo n=84

Post hoc Outcome - Survival to Discharge



Safety - prehospital

Event	Randomization group			
	60 mg (n=497)	45 mg (n=499)	Placebo (n=496)	
ROSC	58%	53%	58%	
Norepinephrine after randomization	16%	16%	15%	
Epinephrine after randomization	95%	95%	95%	
Epinephrine dose (mg)	3.1 <u>+</u> 1.7	3.1 <u>+</u> 1.6	3.2 <u>+</u> 2.0	
	(n=473)	(n=471)	(n=468)	
Rearrest in field (ROSC)	156/294 (53%)	130/270 (48%)	139/291 (48%)	
Systolic BP after	128 <u>+</u> 43	127 <u>+</u> 41	130 <u>+</u> 44	
randomization (mm/Hg)	(n=257)	(n=241)	(n=260)	
Transported to hospital	55%	51%	56%	

Safety - ED and hospital

Characteristic	Randomization group		
	60 mg (n=497)	45 mg (n=499)	Placebo (n=496)
First systolic blood pressure in hospital (mm/Hg)	117 <u>+</u> 35 (n=241)	114 <u>+</u> 34 (n=222)	122 <u>+</u> 36 (n=249)
Sustained hypotension	9/228 (3.9%)	11/216 (5.1%)	14/238 (5.9%)
pH first arterial blood gas	7.1 <u>+</u> 0.2 (n=235)	7.1 <u>+</u> 0.2 (n=222)	7.1 <u>+</u> 0.2 (n=235)
Pressors in first 24 hours	185/272 (68%)	173/255 (68%)	190/278 (68%)
Hospital targeted temperature management	139/272 (51%)	130/255 (51%)	136/278 (49%)
First hospital temperature	35.3 <u>+</u> 1.7 (n=226)	35.3 <u>+</u> 1.8 (n=205)	35.1 <u>+</u> 2.0 (n=220)
Withdrawal of life sustaining therapies	112/272 (41%)	109/255 (43%)	124/277 (45%)
Rearrest first 24 hours of hospitalization	74/271(27%)	65/249 (28%)	76/271 (28%)
ICU days (median)	5.3 (n=68)	5.1 (n=56)	4.6 (n=77)

Conclusions

- Sodium nitrite for out-of-hospital cardiac arrest did not significantly improve survival to hospital admission or to discharge
- Sodium nitrite is not associated with substantive or significant adverse effects on hemodynamics

Acknowledgements

Paramedics in Seattle and King County

HOSPITALS: Harborview Medical Center, Swedish Medical Center, Virginia Mason Hospital, UWMC, Northwest Hospital, Overlake Hospital, Valley Medical Center, Auburn General Hospital, St. Francis Hospital

DSMB: Chair: Susan Stern, MD. Members: Kyra Becker, MD, David Shavelle MD (USC), Dave Beiser MD(Univ. of Chicago), Al Hallstrom PhD

Funding: NIH/NHLBI